All In Biotech

BLA 019774 · Ferring

Zomacton

Somatropin · Injection

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

May 25, 1995

Approved uses

7

Original approval plus efficacy supplements

Registered trials

540

176 Phase 3, 31 recruiting

FAERS reports

6,235

4,338 serious, 351 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 20, 2026.

ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 ) 1.1 Pediatric Patients ZOMACTON is indicated for the treatment of pediatric patients with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), height standard deviation score (HSDS) ≤-2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range, short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. 1.2 Adult Patients ZOMACTON is indicated for the replacement of endogenous GH in adults with GH deficiency.

Mechanism: Somatropin binds to dimeric GH receptors located within the cell membranes of target tissue cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or effects mediated indirectly by IGF-1, including stimulation of chondrocyte differentiation, and proliferation, stimulation of hepatic glucose output, protein synthesis, and lipolysis. Somatropin stimulates skeletal growth in pediatric patients with...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 19, 2018 Supplement 49 · Efficacy LetterLabel
  • Jul 19, 2018 Supplement 51 · Efficacy LetterLabel
  • Jul 19, 2018 Supplement 48 · Efficacy LetterLabel
  • Jul 19, 2018 Supplement 50 · Efficacy LetterLabel
  • Jan 30, 2018 Supplement 45 · Efficacy LetterLabel
  • Jan 30, 2018 Supplement 40 · Efficacy LetterLabel
  • May 25, 1995 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • ZOMACTON · SOMATROPIN 10MG/VIAL · INJECTABLE, INJECTION · Prescription
  • BIO-TROPIN · SOMATROPIN 4.8MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • ZOMACTON · SOMATROPIN 5MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.

All 540 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use428
  • device leakage334
  • headache255
  • injection site pain253
  • drug dose omission by device219
  • fatigue165
  • drug ineffective157
  • device mechanical issue150
  • device issue139
  • pyrexia132
  • sleep apnoea syndrome122
  • product dose omission issue121

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200439
200513
200626
2007109
200846
2009213
2010164
2011196
2012217
2013107
2014168
2015244
2016374
2017278
2018277
2019485
2020366
2021269
2022465
2023742
2024685
2025450
2026302

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Nov 13, 2026

    Zomacton, Injection, 5 mg; 4.8 mg; 10 mg (NDC 55566-1801-1). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zomacton (Somatropin)

2024 spending

$62K

Beneficiaries

n/a

46 claims

Per beneficiary

n/a

$515.45 per unit

View as table
YearSpending
2020$151,217
2021$83,705
2022$0
2023$68,423
2024$61,792

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 81 on PubMed

Sponsor: Ferring · Also marketed as Bio-Tropin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.